Freenome (FRNM) Q3 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 earnings summary
29 Aug, 2026Executive summary
Incorporated on March 22, 2024, as a blank check company to pursue a business combination; no operating revenues to date, only interest income from trust account investments.
Completed IPO on June 13, 2024, raising $86.25 million from 8,625,000 Class A shares, including full over-allotment exercise.
Simultaneously sold 286,250 private placement shares for $2.86 million to the sponsor.
Net income for Q3 2024 was $981,482, driven by interest income and unrealized gains, offset by operating expenses.
Financial highlights
For Q3 2024: net income of $981,482; for the period since inception: net income of $1,068,960.
Interest income on trust account investments was $1,163,406 for Q3 and $1,365,738 since inception.
Operating expenses were $196,128 for Q3 and $318,079 since inception.
Cash and investments in trust account totaled $87,637,039 as of September 30, 2024.
Cash outside the trust account was $1,209,453; working capital was $1,209,805 at quarter end.
Outlook and guidance
Plans to use IPO and private placement proceeds to complete a business combination by June 13, 2026.
No assurance of successful completion of a business combination; mandatory liquidation if not completed by deadline.
May need additional financing if costs exceed estimates or if significant redemptions occur at business combination.
Latest events from Freenome
- IPO filing details a well-funded, AI-driven cancer screening innovator with FDA approval and major partnerships.FRNM
Registration filing - SPAC raised $86.25M, reports $1.91M net income, must acquire or liquidate in 24 months.FRNM
Q4 2024 - SPAC holds $91.9M in trust, targets Freenome merger in 2026, but faces going concern risks.FRNM
Q4 2025 - Vote sought to extend business combination deadline by one year, with redemption rights offered.FRNM
Proxy filing - Q1 2025 net income reached $678,555, with $90.6M in assets and ongoing exposure to global market risks.FRNM
Q1 2025 - Q1 2026 saw a net loss and rising expenses as the company pursues the Freenome merger.FRNM
Q1 2026 - Q2 2025 net income reached $754,847, with ongoing risks tied to business combination completion.FRNM
Q2 2025 - Vote sought to extend merger deadline by one year; redemption rights and board support highlighted.FRNM
Proxy filing - IPO completed, $86.25M raised; Q2 net income $102,875; business combination targeted by June 2026.FRNM
Q2 2024